Study shows a changed microbiome in the lower airways for sarcoidosis patients

Sarcoidosis is a systemic inflammatory disease that is difficult to diagnose and treat, partly because its cause and mechanism remain unclear. It is characterized by the formation of immune cell clusters called granulomas, primarily in the lungs. Given the involvement of this immune response, sarcoidosis may be caused by an infectious pathogen.

It was long assumed that the lower airways were sterile, but it has now been established that the airways have their own "microbiome". This is a collective term for the microbes that are present in the airways at all times.

The MicroILD study investigated 35 sarcoidosis patients and 35 healthy controls. Compared with healthy controls, patients with sarcoidosis had a different microbiome in their lungs. In particular, there was an excess of the fungal species Aspergillus in the lower airways and lower levels of antimicrobial peptides in sarcoidosis patients compared to healthy controls.

The study indicates a possible connection between the microbiome in the lower airways and disease development in sarcoidosis.

- This is one of few studies that shows a changed microbiome in the lower airways for sarcoidosis-patients, explains PhD-candidate at the University of Bergen, Kristel Knudsen.

Source:
Journal reference:

Knudsen, K.S., et al. (2022) The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis. Microbiome. doi.org/10.1186/s40168-022-01362-4.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights benefits and risks of doxy-PEP for STI prevention